

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

SUPPLEMENTAL ANNOUNCEMENT ON CONNECTED TRANSACTION IN RELATION TO SHARE PURCHASE PURSUANT TO SHARE AWARD SCHEME

Reference is made to the announcements of LifeTech Scientific Corporation (先健科技公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 27 June 2024 (the “**June 2024 Announcement**”) and 9 December 2025 (the “**December 2025 Announcement**”) in relation to the share purchases pursuant to the Share Award Scheme. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the December 2025 Announcement.

Further to the December 2025 Announcement, the Board would like to provide additional information on the Transaction.

Consideration

The consideration of the Transaction referenced the average closing prices per Share for the last 30, 60, and 90 consecutive trading days including the date of the Agreement in the December 2025 Announcement, which reflected market levels over a longer period. The Company considers that market environment including factors such as industry and sector volatility and broader market adjustments immediately prior to the Transaction had led to a temporary decrease in Share price, resulting in the consideration of the Shares being higher than the closing price of the Shares on the date of the Agreement. On December 8, 2025, the Beijing Municipal Medical Insurance Bureau initiated supply confirmation works for “volume-based procurement of medical consumables in the electrophysiology and neuro-intervention categories (coils, intracranial stents, and flow-diverting

dense-mesh stents) for hospital groups” (電生理類、神經介入類 (彈簧圈、顱內支架、血流導向密網支架) 醫用耗材醫院集團帶量採購) for relevant enterprises, which led to heightened market concerns about profit margins being compressed in the medical device industry and triggering a sector-wide pullback which also affects share prices of Hong Kong-listed medical device companies. In the same week of the Transaction, the Hang Seng Healthcare Index also fell by approximately 2.3% and underperformed the Hang Seng Index. Furthermore, considering the Shares were not actively traded previously (averaging approximately 30 million Shares in daily trading volume during 2025 up to the date of the Transaction), the Company considers that a reference to the medium- to long-term price range of the Shares as set out in the December 2025 Announcement would better reflect a fair market value.

The consideration of HK\$1.900 per Sale Share for the Transaction represents:

- (a) a premium of approximately 0.11% to the average closing price of HK\$1.898 per Share for the last five consecutive trading days including the date of the Agreement; and
- (b) a premium of approximately 1.12% to the average closing price of HK\$1.879 per Share for the last 10 consecutive trading days including the date of the Agreement.

The Company considers that the consideration of the Transaction falls between the prevailing market price at the time of the Agreement and the medium- to long-term fair value of the Shares, which balances the interests of all parties and ensures that the Company acquired Shares at a reasonable cost while also complimenting the will of Mr. XIE Yuehui’s (“**Mr. XIE**”), the executive Director, chairman and chief executive officer and a substantial shareholder of the Company, to support the Company’s development. The Company is optimistic about its future development and business layout, long-term prospects and believes that the Transaction was completed at a relatively low cost and with high efficiency, which is in line with the Company’s expectations and long-term interests.

For completeness, the consideration of HK\$1.500 per sale share pursuant to the June 2024 Announcement represents:

- (a) a premium of approximately 4.02% to the average closing price of HK\$1.442 per Share for the last five consecutive trading days including the date of the Agreement (as defined under the June 2024 Announcement); and
- (b) a premium of approximately 0.60% to the average closing price of HK\$1.491 per Share for the last 10 consecutive trading days including the date of the Agreement (as defined under the June 2024 Announcement).

Corporate governance

To address potential conflicts, the Company has undertaken not to grant any awards pursuant to the Share Award Scheme to Mr. XIE personally or to his associates (as defined in the Listing Rules) for the remainder of the Share Award Scheme. Mr. XIE has also undertaken to the Company not to accept any awards granted to him personally (if any) pursuant to the Share Award Scheme for the remainder of the Share Award Scheme.

Based on the above, the Directors (including the independent non-executive Directors) are of the view that the Transaction and its consideration to be fair and reasonable and in the interests of the Company and its Shareholders as a whole.

Adjustment of the limit for the 2019 Share Award Scheme and the Share Award Scheme

On 13 February 2026, the Board approved, ratified and confirmed the adjustment of the respective limits for the 2019 Share Award Scheme and the Share Award Scheme by allocating the unused limit in the 2019 Share Award Scheme (i.e. 121,009,120 Shares) to the Share Award Scheme. The aforesaid adjustment does not result in any increase in the aggregate limit of the 2019 Share Award Scheme and the Share Award Scheme taken as a whole (i.e. 896,632,160 Shares). Upon completion of such adjustment, the limit of the Share Award Scheme became 584,012,160 Shares and the number of share awards that may be granted under the Share Award Scheme was 481,916,160. Also, given that there is no involvement of any new Shares, there is no dilution effect from any of such schemes.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui

Executive Director, Chairman and Chief Executive Officer

Hong Kong, 27 February 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.